Please assess the completion status of the following clinical trial:

Trial Title: Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and Healthy Controls

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. For all participants:~* Age 18 years or older~* Able to understand and grant informed consent~* Able to have their blood drawn at enrollment before surgery and 7 to 28 days after surgery~For participants with early stage solid tumors:~* Diagnosed with an early stage (I-III) solid tumor with curative intent surgery without neoadjuvant therapy planned~For healthy control subgroup:~* No prior or current diagnosis of any cancer. Participants with prior in situ cancer or non-melanoma skin cancer will be allowed to participate but will not be included in the healthy control cohort and will be analyzed separately.~Exclusion Criteria:~* Unable to grant informed consent or comply with all study procedures~* Diagnosed with a hematological malignancy (acute or chronic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myeloma or lymphoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Early stage neoplasm (Type: None): Patients with stage I-III early stage non-hematologic neoplasm
- Healthy Control (Type: None): Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).